Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)

Rationale and Design of the Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation (THE BALANCE) Study

(2010) William T. Abraham et al.   CTS-Clinical and Translational Science

Tolvaptan

(2010) Greg L. Plosker   DRUGS

A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose–response of tolvaptan in patients with decompensated liver cirrhosis

(2010) Kiwamu Okita et al.   JOURNAL OF GASTROENTEROLOGY

Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis

(2010) Florence Wong et al.   JOURNAL OF HEPATOLOGY

Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia

(2010) T. Berl et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience

(2010) J. C. Q. Velez et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Conivaptan: promise of treatment in heart failure

(2009) Mohammad Z Hoque et al.   EXPERT OPINION ON PHARMACOTHERAPY

Vasopressin-receptor antagonists in heart failure

(2008) T. A. Schweiger et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia

(2008) John J. Finley et al.   CIRCULATION

Pharmacology of vasopressin antagonists

(2008) Lisa C. Costello-Boerrigter et al.   HEART FAILURE REVIEWS

Effects of satavaptan, a selective vasopressin V2receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial

(2008) Pere Ginès et al.   HEPATOLOGY

Efficacy and Safety of the Vasopressin V1A/V2-Receptor Antagonist Conivaptan in Acute Decompensated Heart Failure: A Dose-Ranging Pilot Study

(2008) Steven R. Goldsmith et al.   JOURNAL OF CARDIAC FAILURE

Effects of Novel Vasopressin Receptor Antagonists on Renal Function and Cardiac Hypertrophy in Rats with Experimental Congestive Heart Failure

(2008) B. Bishara et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction

(2008) James E. Udelson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY